Vident Investment Advisory’s Adaptimmune Therapeutics ADAP Stock Holding History

Vident Investment Advisory’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-133,240	Closed	-$1.06M	–	894
2020 Q3	$1.06M	Sell	133,240 -7,289	-5%	-$63.8K	0.05%	468
2020 Q2	$1.41M	Buy	+140,529	New	+$883K	0.07%	353
2019 Q2	–	Sell	-289,340	Closed	-$1.24M	–	442
2019 Q1	$1.24M	Sell	289,340 -9,510	-3%	-$44.3K	0.07%	378
2018 Q4	$1.72M	Buy	298,850 +106,599	+55%	+$787K	0.1%	289
2018 Q3	$2.61M	Sell	192,251 -13,450	-7%	-$141K	0.1%	270
2018 Q2	$2.44M	Sell	205,701 -25,648	-11%	-$320K	0.1%	283
2018 Q1	$2.87M	Buy	231,349 +61,943	+37%	+$542K	0.12%	253
2017 Q4	$1.13M	Sell	169,406 -81,739	-33%	-$631K	0.05%	364
2017 Q3	$2.06M	Buy	251,145 +7,610	+3%	+$47.5K	0.11%	278
2017 Q2	$1.09M	Buy	243,535 +10,894	+5%	+$56.9K	0.09%	313
2017 Q1	$1.28M	Buy	232,641 +38,772	+20%	+$170K	0.13%	291
2016 Q4	$785K	Buy	193,869 +120,724	+165%	+$579K	0.1%	294
2016 Q3	$516K	Sell	73,145 -427	-0.6%	-$3.26K	0.07%	338
2016 Q2	$600K	Sell	73,572 -67,514	-48%	-$636K	0.08%	357
2016 Q1	$1.15K	Buy	141,086 +65,546	+87%	+$536K	0.07%	348
2015 Q4	$911K	Buy	+75,540	New	+$740K	0.12%	321

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vident Investment Advisory's ADAP Position: Q4 2020 in Review

Vident Investment Advisory sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 133,240 shares — an estimated $1.06M sold.

Vident Investment Advisory first reported a position in ADAP in Q4 2015 and held it in 16 quarters. The position peaked at $2.87M in Q1 2018. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

Vident Investment Advisory reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Vident Investment Advisory sold 133,240 Adaptimmune Therapeutics shares in Q4 2020, an estimated $1.06M.
Vident Investment Advisory first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 16 quarters.
Vident Investment Advisory's Adaptimmune Therapeutics position peaked at $2.87M in Q1 2018.
87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Vident Investment Advisory's 13F filing for Q4 2020, filed 8 Feb 2021.